Discover more from FarmaKology’s Substack
FarmaKology Newsletter - Issue #18
Kite Pharma, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development.For the past three decades, members of our team have been at the forefront of cancer immunotherapy.
Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
Inovio Pharmaceuticals, a Montgomery County biotechnology company, closed a $15 million private placement of convertible bonds — and disclosed plans to pursue a secondary listing on the KOSDAQ exchange in Korea.If it is successful, Invoio (Nasdaq: INO) said it would become the first U.S.-based Nasdaq company to dually list its stock on the Korean exchange.
German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline.
Athenex, Hanmi’s U.S. partner, presented the topline data showing that Oraxol, an oral anti-cancer drug, met the primary efficacy endpoint with statistically significant improvement over IV paclitaxel in a phase 3 study in metastatic breast cancer.
China's cosmetic surgery market is growing so fast it is expected to top the world by 2019 in terms of cosmetic procedures performed, according to a new white paper released on Wednesday by SoYoung, a leading Chinese online platform for cosmetic surgery.